Anavex Life Sciences Corp.

Anavex Life Sciences Corp. Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics The Michael J.

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarca

mesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com

Pharmacogenomics may help identify which Alzheimer’s patients respond best to treatment.Research suggests patients with ...
03/10/2026

Pharmacogenomics may help identify which Alzheimer’s patients respond best to treatment.

Research suggests patients with SIGMAR1 + COL24A1 wild-type profiles (~50%) may show enhanced response to blarcamesine.

Precision medicine approaches like HER2, BRAF, and CFTR testing are now expanding into neurodegenerative disease.

On Rare Disease Day, we stand with the millions of families around the world navigating the challenges of rare diseases ...
02/28/2026

On Rare Disease Day, we stand with the millions of families around the world navigating the challenges of rare diseases every day.

Behind every diagnosis is a story of strength, resilience, and hope. Today, February 28, 2026, we honor the patients, caregivers, advocates, clinicians, and researchers working tirelessly to bring greater awareness, understanding, and innovation to the rare disease community.

Address

51 W 52nd Street
New York, NY
10111

Website

Alerts

Be the first to know and let us send you an email when Anavex Life Sciences Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Anavex Life Sciences Corp.:

Shortcuts

Share

Category